RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES
Clinical trials for RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES trials appear
Sign up with your email to follow new studies for RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…
Matched conditions: RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells…
Matched conditions: RECURRENT OR REFRACTORY DISEASE AFTER STANDARD THERAPIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC